Stockscreener 앱 받기
4.195
1.86%
0.105
전일 마감가:
$4.30
열려 있는:
$5.03
하루 거래량:
10.67M
Relative Volume:
2.43
시가총액:
$960.06M
수익:
-
순이익/손실:
$-283.26M
주가수익비율:
-2.8537
EPS:
-1.47
순현금흐름:
$-273.61M
1주 성능:
+156.14%
1개월 성능:
+76.61%
6개월 성능:
-15.44%
1년 성능:
-39.00%
1일 변동 폭
$4.17
$5.16
1주일 범위
$1.64
$7.30
52주 변동 폭
$1.52
$12.00
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 400, SEATTLE
SANA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
4.20 | 960.06M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.01 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.32 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.80 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.98 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.65 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Shares of Sana soar following breakthrough in diabetes therapy trials - Kursiv Media
Cowen Pounds the Table on Sana Biotechnology Stock - TipRanks
First data for immune-evading type 1 diabetes therapy trigger Sana stock surge - FirstWord Pharma
Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type - openPR
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement - MSN
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance - BioWorld Online
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
TD Cowen Upgrades Sana Biotechnology (SANA) - MSN
Sana Biotech extends rally as Morgan Stanley cites platform's potential - MSN
Sana Biotech stock jumps on cell therapy data (SANA:NASDAQ) - Seeking Alpha
Buy reiterated for Sana stock after Phase 1 data supports unique HIP cell platform - Investing.com India
Sana Biotechnology skyrockets on positive diabetes study data - Proactive Investors USA
Sana’s stock soars on new cell therapy data; UniQure’s $75M offering - Endpoints News
TD Cowen lifts Sana Biotech stock rating on positive IST data - Investing.com Canada
Sana Biotechnology (SANA), eBay (EBAY) Are Among Today’s Big Winners - Insider Monkey
Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts - Fierce Biotech
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success - Seeking Alpha
Sana Biotechnology (NASDAQ:SANA) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
This Biotech Stock Soared 300% Overnight. Why It Can Go Higher. - Yahoo! Voices
HC Wainwright Boosts Sana Biotechnology (NASDAQ:SANA) Price Target to $11.00 - MarketBeat
Sana Biotechnology Stock Surges Over 200% On WednesdayHere's Why - Benzinga
Sana stock soars on positive T1D study results, BofA maintains Buy - Investing.com Nigeria
Sana stock soars on positive T1D study results, BofA maintains Buy By Investing.com - Investing.com South Africa
Sana Biotechnology (NASDAQ:SANA) Soars 400% on Breakthrough Diabetes Transplant - TipRanks
Sana Biotechnology (NASDAQ:SANA) Upgraded to "Buy" at TD Cowen - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Sana Biotechnology price target lowered to $7 from $8 at BofA - Yahoo Finance
This Biotech Stock Just Soared 240%. Why It Can Go Higher. - Barron's
Sana stock soars on positive diabetes study data By Investing.com - Investing.com South Africa
Sana stock soars on positive diabetes study data - Investing.com
Sana Biotechnology Shares Spike Following Successful Transplantation - AllSides
Sana Biotechnology could offer relief to diabetes type 1 sufferers in the future - Mugglehead
Stocks to Watch: Sana Biotechnology, Richardson Electronics, Maplebear - MarketWatch
Sana Biotech’s islet cell therapy shows promise in diabetes; shares surge 150% postmarket - Investing.com Nigeria
Sana Biotechnology announces initial results from type 1 diabetes study - TipRanks
Sana Biotech's islet cell therapy shows promise in diabetes; shares surge 150% postmarket - Investing.com
Sana Biotechnology Announces Positive Clinical Results from - GlobeNewswire
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell - The Bakersfield Californian
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Seattle InnoSana and Bothell I Following up with ZenLedger - The Business Journals
Geode Capital Management LLC Purchases 276,055 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Stifel Financial Corp Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology stock hits 52-week low at $1.54 By Investing.com - Investing.com Nigeria
Sana Biotechnology stock hits 52-week low at $1.54 - Investing.com
Barclays PLC Acquires 178,179 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
Sana Biotechnology Drops To US$1.63, Yet Insiders May Have Sold Too Early - Simply Wall St
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by State Street Corp - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology stock hits 52-week low at $1.8 amid downturn - Investing.com Canada
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
0.45%
자본화:
|
볼륨(24시간):